MedTrace Logo

Transfusion in Sickle Cell Disease: Screening of Sickle Cell Disease Trait in Blood Donors

NCT03405688 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 173

Last updated 2021-01-28

No results posted yet for this study

Summary

Bearers of the sickle cell allele (S) are currently eligible for blood donations in Belgium. As blood donors are not tested for this allele, their heterozygous status is unknown. However, guidelines recommend to transfuse sickle cell patients with blood that is negative for the 'S' hemoglobin. To the investigator's knowledge, no study has been conducted to evaluate the impact of transfusion with blood originating from heterozygous donors on the transfusion performance and the improvement of clinical status of the sickle cell disease patients.

Conditions

Interventions

PROCEDURE

Blood sampling

Extra blood samples taken for laboratory analysis

Sponsors & Collaborators

  • Hanane EL KENZ

    lead OTHER

Principal Investigators

  • Marie Deleers, Ph Biol · CHU Brugmann

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-13
Primary Completion
2020-08-03
Completion
2020-08-03

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03405688 on ClinicalTrials.gov